BIOMARK Closes First Tranche of Over-Subscribed Private
2017, 29 JUNE
Vancouver, British Columbia – (June 29. 2017) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that further to its press release of May 9th, 2017, it has closed the first tranche of a non-brokered private placement for gross proceeds of $ 639,790.87 wherein BioMark issued 6,397,909 units at a price of $ 0.10 per unit. The Company anticipates closing another tranche within 4 weeks estimated around $ 470,000.00.
Each unit consists of one common share of BioMark and one-half of one share purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share of BioMark at $0.15 per share for a period of two years from the closing date of the private placement, subject to an acceleration clause. The Company will pay finders’ fees in accordance with CSE policies of a total of $ 21,600.00 and issue a total of 216,000 finders’ warrants where each Finders’ Warrant entitles the holder to acquire one share a price of $ 0.15 for a period of two years from the closing date of the private placement, subject to an acceleration clause.
The proceeds of the private placement will be used for the continuation of the company’s phase three clinical trials, regulatory submission costs, marketing initiatives and general working capital. The securities issued under the private placement will be subject to a hold period of four months and one day.
Press Release – Biomark Closes First Tranche of Private Placement Offering (PDF)
BIOMARK Announces Private Placement
2017, 9 MAY
Vancouver, British Columbia – (May 9. 2017) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS:BMKDF) is pleased to announce a non-brokered Private Placement (the “Offering”). The Offering will be for up to 5,000,000 Units at a price of $0.10 to raise gross proceeds of up to $500,000.
Each Unit is composed of one common share (a “Share”) of the Company and one-half of a Share purchase warrant (a “Warrant”). Each whole Warrant shall entitle the holder to acquire one Share at a price of $0.15 per Share for a period of two years after the date of issuance. Finder’s fees may be payable. The private placement and finder’s fees are subject to regulatory approval.
The proceeds of the Offering will be used for the regulatory submission activities, further product development, marketing initiatives and general working capital. The securities in the private placement will be subject to a holding period of four months from the closing date of the private placement. Certain Insiders, Directors and Officers may subscribe for a portion of this placement. Closing of the private placement is subject to the Canadian Securities Exchange approval.
BIOMARK Selected to Pitch at 2017 BCTECH Summit
2017, 16 MARCH
Vancouver, British Columbia – (March 16. 2017) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) is proud to announce that was selected to pitch at #BCTECH Summit, during the Investment Showcase that was scheduled for March 15th 2017 at Vancouver Convention Centre.
President and CEO, Rashid Ahmed says, “BioMark is excited to be amongst the top selected companies to showcase our leading edge cancer diagnostic platform to a dynamic financial investment, government and biotechnology global community”.
About BCTECH Summit
The #BCTECH Summit is the largest technology conference in British Columbia showcasing the province’s vibrant technology industry. From innovations in eHealth data, autonomous vehicles and customer experience, to emerging ideas in cleantech, agritech and aerospace, the two-day event will give you the information and tools you need to move forward in a world where technology is impacting every part of our economy – and our lives.
The #BCTECH Summit brings together tech entrepreneurs, anchor companies, business leaders from traditional industries, investors, government and academia to establish new connections, nurture existing networks, and exchange fresh ideas around innovation driving business growth.
More about the summit is available at http://bctechsummit.ca/
News Release – BIOMARK Selected To Pitch At BCTech Summit 2017 (PDF)
BioMark Diagnostics to Conduct Validation Studies for its Patented Assays in Patients with Lung Cancer
Dr. James Bond of Surrey Memorial Hospital to act as Principal Investigator
2015, 10 SEPTEMBER
BioMark Diagnostics to Conduct Validation Studies (PDF)
BioMark Diagnostics Unveils U.S. Strategy
2015, 13 AUGUST
Biomark US Strategy (PDF)
BioMark Diagnostics Engages LHA for Investors Relations
2015, 29 JUNE
BioMark Engages LHA (PDF)